NEW YORK (GenomeWeb News) – Optivia Biotechnology today said that it will collaborate with the US Food and Drug Administration on identifying potentially harmful drug-dietary supplement interactions.
Under the collaboration, seven key drug transporters associated with drug-drug interactions will be examined using Optivia's in vitro transporter technology platform, which uses polarized mammalian cell assays that closely model human biology. The collaboration will assess the ability of certain dietary supplements, such as black cohosh, green tea, ginko biloba, kava, usnic acid,0 and others, to affect various drug transporters.
The goal of the collaboration is to identify potentially harmful drug-dietary supplement interactions, such as the interaction of acetaminophen and other drugs associated with liver toxicity, said Menlo Park, Calif.-based Optivia.